JP2018534306A5 - - Google Patents

Download PDF

Info

Publication number
JP2018534306A5
JP2018534306A5 JP2018524824A JP2018524824A JP2018534306A5 JP 2018534306 A5 JP2018534306 A5 JP 2018534306A5 JP 2018524824 A JP2018524824 A JP 2018524824A JP 2018524824 A JP2018524824 A JP 2018524824A JP 2018534306 A5 JP2018534306 A5 JP 2018534306A5
Authority
JP
Japan
Prior art keywords
wound
medicament
dose
plasminogen
biologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018524824A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018534306A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2016/001606 external-priority patent/WO2017081529A1/en
Publication of JP2018534306A publication Critical patent/JP2018534306A/ja
Publication of JP2018534306A5 publication Critical patent/JP2018534306A5/ja
Pending legal-status Critical Current

Links

Images

JP2018524824A 2015-11-10 2016-11-10 創傷治癒のためのプラスミノーゲン投与計画 Pending JP2018534306A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562253352P 2015-11-10 2015-11-10
US62/253,352 2015-11-10
PCT/IB2016/001606 WO2017081529A1 (en) 2015-11-10 2016-11-10 Plasminogen dosage regimen for wound healing

Publications (2)

Publication Number Publication Date
JP2018534306A JP2018534306A (ja) 2018-11-22
JP2018534306A5 true JP2018534306A5 (cg-RX-API-DMAC7.html) 2019-12-19

Family

ID=57485826

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018524824A Pending JP2018534306A (ja) 2015-11-10 2016-11-10 創傷治癒のためのプラスミノーゲン投与計画

Country Status (14)

Country Link
US (1) US20180326023A1 (cg-RX-API-DMAC7.html)
EP (1) EP3373957A1 (cg-RX-API-DMAC7.html)
JP (1) JP2018534306A (cg-RX-API-DMAC7.html)
KR (1) KR20180070708A (cg-RX-API-DMAC7.html)
CN (1) CN108289934A (cg-RX-API-DMAC7.html)
AU (1) AU2016352183A1 (cg-RX-API-DMAC7.html)
BR (1) BR112018009476A8 (cg-RX-API-DMAC7.html)
CA (1) CA3004509A1 (cg-RX-API-DMAC7.html)
IL (1) IL259172A (cg-RX-API-DMAC7.html)
MX (1) MX2018005876A (cg-RX-API-DMAC7.html)
RU (1) RU2018121234A (cg-RX-API-DMAC7.html)
TW (1) TW201722464A (cg-RX-API-DMAC7.html)
WO (1) WO2017081529A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201803010B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI868051B (zh) * 2017-06-23 2025-01-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
CN111432762B (zh) * 2017-12-15 2023-01-13 墨尼克医疗用品有限公司 预防性敷料
BR112020003022A2 (pt) 2017-12-26 2020-08-25 Hirotaro Fukuoka composição farmacêutica para o uso no crescimento de cabelo, modificação do couro cabeludo ou pele, cicatrização de uma ferida, promoção da osteogênese ou modificação do cabelo
JP7682567B2 (ja) * 2020-11-17 2025-05-26 泰▲倫▼基国▲際▼有限公司 Ngfレベルを増加させる方法及び薬剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067492B2 (en) * 2001-09-06 2006-06-27 Omnio Ab Method of promoting healing of a tympanic membrane perforation
GB0509438D0 (en) 2005-05-09 2005-06-15 Prometic Biosciences Ltd Affinity adsorbets for fibrinogen
EP2249863A4 (en) * 2008-01-22 2011-12-28 Omnio Healer Ab METHOD OF ENHANCING WOUND HEALING
CA2823491A1 (en) 2011-01-05 2012-07-12 Thrombogenics Nv Plasminogen and plasmin variants
CA2844644A1 (en) 2011-08-12 2013-02-21 Thrombogenics N.V. Plasminogen and plasmin variants
PY1577621A (es) * 2014-12-19 2017-10-02 Prometic Biotherapeutics Inc Composicion farmaceutica que comprende plasminogeno y uso para el mismo
TWI801331B (zh) * 2015-11-03 2023-05-11 美商波麥堤克生物治療股份有限公司 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法

Similar Documents

Publication Publication Date Title
ES2347254T3 (es) Utilizacion de treprostinil para el tratamiento de las lesiones isquemicas.
TWI685348B (zh) 速效胰島素組合物
Bhat Pyoderma gangrenosum: an update
JP2007514749A5 (cg-RX-API-DMAC7.html)
CA2703234C (en) An inhalable dry powder formulation comprising glp-1 for use by pulmonary inhalation
JP2014530873A5 (cg-RX-API-DMAC7.html)
ME02662B (me) Niskofrekventna terapija glatiramer acetatom
RU2004124387A (ru) Системы введения лекарственных средств, содержащих рапамицин и его производные, которые предназначены для предупреждения и лечения сосудистых заболеваний
JP2015512927A5 (cg-RX-API-DMAC7.html)
CN105853421A (zh) FoxO1选择性抑制剂AS1842856的新用途
JP2020526525A5 (cg-RX-API-DMAC7.html)
JP2006527234A5 (cg-RX-API-DMAC7.html)
CN105535001A (zh) 红景天苷在制备治疗糖尿病足的药物中的应用
RU2018121234A (ru) Схема лечения плазминогеном для заживления раны
Kallio et al. Hyperbaric articaine for day-case spinal anaesthesia
JP2020510028A5 (cg-RX-API-DMAC7.html)
Yeniocak et al. A basic algorithmic surgical approach for Nicolau syndrome
Yan-Yan et al. Hemocoagulase agkistrodon-induced anaphylactic shock: a case report and literature review
CN110366427A (zh) 一种预防和治疗病理性肾组织损伤的方法
JP6873387B2 (ja) 創傷治癒に対するapc類似体の使用
Qin et al. Transdermal application of azithromycin-amlodipine-heparin gel enhances survival of infected random ischaemic flap
Church et al. Methylene blue for burn-induced vasoplegia: case report and review of literature
NO20044976L (no) Befruktningshindrende middel av en oljeholdig losning for selv-administrering
Voitsekhovsky et al. Individual therapy of patients with hemophilia
Chandy Management of hemophilia with minimal factor replacement in developing countries: role of ancillary therapy